Navigation Links
Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Date:7/1/2011

GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011.  Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md.

For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully human antibodies.  In this position, he held responsibilities for a variety of areas, including corporate development, technical operations, corporate legal, human resources, and public and investor relations.  In 1999, Lemus led the effort to take the company public, successfully completing Germany's first-ever biotech initial public offering.  For the next decade thereafter, he played a central role in helping grow the company into one of Europe's leading life science companies.

"I'm very pleased to become part of the Sigma-Tau growth story going forward as its new vice president of finance," commented Lemus.  "Moreover, Sigma-Tau's considerable expertise in rare diseases will continue to play a decisive role in propelling the company's high rate of growth and expansion over the coming years."

Prior to his role at MorphoSys AG, Lemus was a controller and operations manager at Hoffmann-La Roche, and preceding this position, he served as the treasurer of the Lindt Chocolate Company.

"As a leader in the development and commercialization of medicines for rare diseases, we have undergone tremendous growth in the past few years," said Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc.  "In looking to the future, it's imperative we have talented people like Dave to help Sigma-Tau continue to bring innovation to the field of rare diseases.  We're very pleased to welcome him to the team."

Sigma-Tau Pharmaceuticals, Inc. is dedicated to creating novel medicines for the unmet needs of patients with rare diseases.  

About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases.  Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Md.  Since 1989, the company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the United States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few.  The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria and other areas of unmet medical need.  For more information about the company, visit www.sigmatau.com.


'/>"/>
SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s ... dental services to 1,961 people during the April 22-23 event at the San Mateo ... Californians who experience barriers to care, CDA Cares educates the public and policymakers about ...
(Date:4/24/2017)... Illinois (PRWEB) , ... April 24, 2017 , ... Veteran ... What happened next changed her life forever. , In “Healing Tears,” James depicts every ... the advice of my attorney, I began journaling conversations and situations throughout my divorce,” ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP ... food supplements, announced its popular products are now available for purchase on StackedNutrition.com, ... prioritizes the use of premium natural ingredients in making all of its products. ...
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African ... now available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional ... popularized in ancient India and Siam. It spread across Asia and Africa quickly, and ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, ... credentialing solutions, today announced that Kyle Allain has joined the company as Vice ... sales and operations, including provider, payor and managed care solutions. , A ...
Breaking Medicine News(10 mins):